Founder Securities research report pointed out that establishing the "Scitech Estimation" system is an inevitable requirement for developing new productive forces. Innovative drugs, high-end medical devices, innovative high-value consumables and other medical technologies with high level of "intelligent manufacturing" have accelerated approval and continued to go abroad. Medical new technologies such as brain-computer interface, AI, and biosynthesis are continuously producing and are expected to usher in a valuation reshaping opportunity. 1) Innovative drug sector, pay attention to Jiangsu Hengrui Pharmaceuticals, Beigene and other companies; 2) Medical devices sector, pay attention to GE Healthcare, Shinva Medical and other companies; 3) High-value consumables sector, pay attention to Apt Medical Inc. and other companies; 4) Medical new technology sector, pay attention to ChuanNing Biology and other companies.